Evidence map›Paper›PMID 25305565›Full record

ArticleVaccine2015

The Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG).

Robert T Chen, Baevin Carbery, Lisa Mac, Kenneth I Berns, Louisa Chapman, Richard C Condit, Jean-Louis Excler, Marc Gurwith, Michael Hendry, Arifa S Khan and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Vaccine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed.

  1. Trial
  2. COVID-19 vaccine triggered autoimmune hepatitis: case report.European journal of hospital pharmacy : science and practice · 2023
    Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Review
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. Review
  17. Review
  18. Review
  19. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Robert T ChenDHAP, NCHHSTP, Centers for Disease Control and Prevention, 1600 Clifton Road, Atlanta, GA 30333, USA. Electronic address: brightoncollaborationv3swg@gmail.com.
Baevin CarberyDHAP, NCHHSTP, Centers for Disease Control and Prevention, 1600 Clifton Road, Atlanta, GA 30333, USA; Division of Infectious Diseases, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA.
Lisa MacDHAP, NCHHSTP, Centers for Disease Control and Prevention, 1600 Clifton Road, Atlanta, GA 30333, USA.
Kenneth I BernsDepartment of Molecular Genetics and Microbiology, University of Florida College of Medicine, P.O. Box 100266, Gainesville, FL 32610, USA.
Louisa ChapmanDHAP, NCHHSTP, Centers for Disease Control and Prevention, 1600 Clifton Road, Atlanta, GA 30333, USA.
Richard C ConditDepartment of Molecular Genetics and Microbiology, University of Florida College of Medicine, P.O. Box 100266, Gainesville, FL 32610, USA.
Jean-Louis ExclerInternational AIDS Vaccine Initiative, New York, NY, USA; U.S. Military HIV Research Program (MHRP), Bethesda, MD 20817, USA.
Marc GurwithPaxVax, San Diego, CA 92121, USA.
Michael HendryDHAP, NCHHSTP, Centers for Disease Control and Prevention, 1600 Clifton Road, Atlanta, GA 30333, USA.
Arifa S KhanLaboratory of Retroviruses, Division of Viral Products, Center for Biologics Evaluation and Research, US Food and Drug Administration, Bethesda, MD 20892, USA.
Najwa Khuri-BulosDivision of Infectious Disease, Jordan University Hospital, Amman, Jordan.
Bettina KlugPaul-Ehrlich-Institut, 63225 Langen, Germany.
James S RobertsonIndependent Adviser (formerly of National Institute for Biological Standards and Control, Potters Bar, EN6 3QG, UK).
Stephen J SeligmanDepartment of Microbiology and Immunology, New York Medical College, Valhalla, NY 10595, USA.
Rebecca SheetsDivision of AIDS, National Institute of Allergy and Infectious Diseases, U.S. National Institutes of Health, Bethesda, MD 20892, USA.
Anna-Lise WilliamsonInstitute of Infectious Disease and Molecular Medicine, University of Cape Town and National Health Laboratory Service, Cape Town, South Africa.
V3SWG

Funding

Intramural CDC HHS CC999999
6 · The paper itself

Abstract

Recombinant viral vectors provide an effective means for heterologous antigen expression in vivo and thus represent promising platforms for developing novel vaccines against human pathogens from Ebola to tuberculosis. An increasing number of candidate viral vector vaccines are entering human clinical trials. The Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG) was formed to improve our ability to anticipate potential safety issues and meaningfully assess or interpret safety data, thereby facilitating greater public acceptance when licensed.

Indexed as

Genetic VectorsInternational CooperationClinical Trials as TopicDrug CarriersDrug-Related Side Effects and Adverse ReactionsHumansVaccines, SyntheticViral VaccinesDrug CarriersVaccines, SyntheticViral VaccinesImmunizationSafetyVaccinesViral Vector

Identifiers

PMID25305565
PMCPMC4568939

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.